peptide drug conjugate OPD5
Term · Oncology and biomedicine · MLC-T-ONC-015957
A peptide-drug conjugate (PDC) composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to an as of yet undisclosed alkylating agent, with potential antineoplastic activity. Upon administration, PDC OPD5 is hydrolyzed by peptidases to release the alkylating agent, thereby allowing for specific accumulation of the agent in aminopeptidase-positive tumor cells. This may result in the inhibition of DNA and/or RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells.
| Identifier | MLC-T-ONC-015957 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | PDC OPD5 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015957",
"term": "peptide drug conjugate OPD5",
"field": "Oncology and biomedicine",
"definition": "A peptide-drug conjugate (PDC) composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to an as of yet undisclosed alkylating agent, with potential antineoplastic activity. Upon administration, PDC OPD5 is hydrolyzed by peptidases to release the alkylating agent, thereby allowing for specific accumulation of the agent in aminopeptidase-positive tumor cells. This may result in the inhibition of DNA and/or RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells.",
"synonyms": [
"PDC OPD5"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/peptide-drug-conjugate-opd5/"
}
Record 12,941 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.